| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
From the Faculty of Dentistry, Department of Oral & Maxillofacial Surgery and the Faculty of Medicine, Department of Anesthesiology, National University of Singapore, and the Faculty of Dentistry, Department of Restorative Dentistry, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
Address correspondence and reprint requests to Cliff K. S. Ong, DDS, MS, 435 Orchard Road, Suite #11–02, Wisma Atria, Singapore 238877. Address email to cliffong{at}pacific.net.sg
Our principal objective in this study was to evaluate the potential pain reducing effect of IV midazolam in patients undergoing oral surgery. One-hundred-twenty-five patients with impacted mandibular third molars requiring removal under local anesthetic were randomized into 2 groups. The first group (n = 64) was administered IV midazolam by titration until a clinical end-point of conscious sedation followed by local anesthetic before surgery; the second group (n = 61) was the control and was administered only local anesthetic before surgery. The surgery was performed in a standardized manner in both groups by the same surgeon. Outcome measures were four primary end-points: pain intensity as assessed by a 100-mm visual analogue scale and a 4-point categorized scale hourly for 8 h, time to first analgesic, total analgesic (ibuprofen) consumption over the first 48 h, and a 5-point categorical patient global assessment scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent). Throughout the 8-h investigation period, patients in the midazolam group reported significantly lower pain intensity scores than those in the control group (19.0 ± 13.2 mm versus 28.1 ± 12.8 mm, P < 0.05). The patients in the midazolam group also reported significantly longer time to first analgesic (165.5 ± 56.5 min versus 202.2 ± 79.0 min, P < 0.05), less analgesic consumption (1275 ± 364 mg versus 1688 ± 407 mg, P < 0.001) and better patient global assessment (3.34 ± 0.8 versus 2.4 ± 0.9, P < 0.001). We conclude that systemically administered midazolam is effective in reducing postoperative pain after third molar surgery.
IMPLICATIONS: In this observer blinded study, we found that IV midazolam treatment (0.09 mg/kg) has a pain-reducing effect after third molar surgery, thus improving postoperative pain management.
This article has been cited by other articles:
|
|
 |
|
  B. L. Friedberg and P. F. White Paradoxical Increase in Pain Requirements with Midazolam Premedication * Response Anesth. Analg., October 1, 2004; 99(4): 1268 - 1269. [Full Text] [PDF]
|
|
|
